BRIEF-Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA

Reuters11-17

BRIEF-<a href="https://laohu8.com/S/FBIO">Fortress Biotech</a> Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA

Nov 17 (Reuters) - Fortress Biotech Inc FBIO.O:

FORTRESS BIOTECH INC: ON NOV 14, SENTYNL NOTIFIED CYPRIUM THAT SENTYNL HAD RESUBMITTED THE NDA FOR CUTX-101 TO THE FDA
FORTRESS BIOTECH: CYPRIUM TO RETAIN OWNERSHIP OVER ANY PRV UPON NDA APPROVAL, TO RECEIVE ROYALTIES & UP TO $129 MILLION IN MILESTONES

Source text: [ID:n0001104659-25-112945]

Further company coverage: FBIO.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2584231286?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-17 20:49","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584231286","market":"nz","top_or_hot":-1,"title":"BRIEF-Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/FBIO\">Fortress Biotech</a> Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA</title></head><body><p><span>Nov 17 (Reuters)</span><span> - </span>Fortress Biotech Inc <span>FBIO.O</span>:</p><ul><li><p>FORTRESS BIOTECH INC: ON NOV 14, SENTYNL NOTIFIED CYPRIUM THAT SENTYNL HAD RESUBMITTED THE NDA FOR CUTX-101 TO THE FDA</p></li><li><p>FORTRESS BIOTECH: CYPRIUM TO RETAIN OWNERSHIP OVER ANY PRV UPON NDA APPROVAL, TO RECEIVE ROYALTIES &amp; UP TO $129 MILLION IN MILESTONES</p></li></ul><p>Source text: [ID:n0001104659-25-112945]</p><p>Further company coverage: <span>FBIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-17 20:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-<a href=\"https://laohu8.com/S/FBIO\">Fortress Biotech</a> Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDA</title></head><body><p><span>Nov 17 (Reuters)</span><span> - </span>Fortress Biotech Inc <span>FBIO.O</span>:</p><ul><li><p>FORTRESS BIOTECH INC: ON NOV 14, SENTYNL NOTIFIED CYPRIUM THAT SENTYNL HAD RESUBMITTED THE NDA FOR CUTX-101 TO THE FDA</p></li><li><p>FORTRESS BIOTECH: CYPRIUM TO RETAIN OWNERSHIP OVER ANY PRV UPON NDA APPROVAL, TO RECEIVE ROYALTIES &amp; UP TO $129 MILLION IN MILESTONES</p></li></ul><p>Source text: [ID:n0001104659-25-112945]</p><p>Further company coverage: <span>FBIO.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FBIO","symbol_name":"Fortress Biotech Inc.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nFWN3WT0TZ:1","article_id":"2584231286","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584231286","pubTimestamp":1763383769,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDANov 17  - Fortress Biotech Inc FBIO.O:FORTRESS BIOTECH INC: ON NOV 14, SENTYNL NOTIFIED CYPRIUM THAT SENTYNL HAD RESUBMITTED THE NDA FOR CUTX-101 TO THE FDAFORTRESS BIOTECH: CYPRIUM TO RETAIN OWNERSHIP OVER ANY PRV UPON NDA APPROVAL, TO RECEIVE ROYALTIES & UP TO $129 MILLION IN MILESTONESSource text: [ID:n0001104659-25-112945]Further company coverage: FBIO.O ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FBIO":"Fortress Biotech Inc.","BK4139":"生物科技"},"translate_title":"简介-Fortress Biotech表示，11月14日，Sentynl通知Cyprium，Sentynl已向FDA重新提交了Cutx-101的NDA","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FBIO":0.9},"content_text":"BRIEF-Fortress Biotech Says On Nov 14, Sentynl Notified Cyprium That Sentynl Had Resubmitted The NDA For Cutx-101 To The FDANov 17 (Reuters) - Fortress Biotech Inc FBIO.O:FORTRESS BIOTECH INC: ON NOV 14, SENTYNL NOTIFIED CYPRIUM THAT SENTYNL HAD RESUBMITTED THE NDA FOR CUTX-101 TO THE FDAFORTRESS BIOTECH: CYPRIUM TO RETAIN OWNERSHIP OVER ANY PRV UPON NDA APPROVAL, TO RECEIVE ROYALTIES & UP TO $129 MILLION IN MILESTONESSource text: [ID:n0001104659-25-112945]Further company coverage: FBIO.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2584231286","isCrawlerRequest":true}